Chemistry:Glycopyrronium tosylate
From HandWiki
Short description: Chemical compound
 | |
| Clinical data | |
|---|---|
| Trade names | Qbrexza, Rapifort |
| Other names | Glycopyrronium tosilate hydrate (JAN JP) |
| AHFS/Drugs.com | Monograph |
| License data | |
| Routes of administration | Topical |
| Drug class | Muscarinic antagonist |
| ATC code | |
| Legal status | |
| Legal status | |
| Identifiers | |
| CAS Number | |
| PubChem CID | |
| DrugBank | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEMBL | |
| Chemical and physical data | |
| 3D model (JSmol) | |
| |
| |
Glycopyrronium tosylate, sold under the brand name Qbrexza among others, is a medication used for the treatment of primary axillary hyperhidrosis.[1][2][3]
It was approved for medical use in the United States in June 2018,[4] and in Japan in January 2022.[5]
References
- ↑ 1.0 1.1 "Qbrexza- glycopyrronium cloth". 17 January 2022. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6b985380-1256-4fb3-b89a-6df2c6a6d12e.
- ↑ "Glycopyrronium Tosylate (Qbrexza) for Hyperhidrosis". Skin Therapy Letter 24 (2): 1–3. March 2019. PMID 30970203.
- ↑ "Topical Glycopyrronium Tosylate in Primary Axillary Hyperhidrosis: A Profile of Its Use". Clinical Drug Investigation 39 (11): 1141–1147. November 2019. doi:10.1007/s40261-019-00853-x. PMID 31571127.
- ↑ "Drug Approval Package: Qbrexza (glycopyrronium)". 20 November 2018. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210361Orig1s000TOC.cfm.
- ↑ "Maruho Launches Primary Axillary Hyperhidrosis Treatment". 23 May 2022. https://www.maruho.co.jp/english/information/20220523.html.
External links
- "Glycopyrronium tosylate". Drug Information Portal. U.S. National Library of Medicine. https://druginfo.nlm.nih.gov/drugportal/name/glycopyrronium%20tosylate.
 |  |
